Tumour marker dropped from 15,000 to 4,178: Stage IV Bile Duct Cancer Patient's Tumour Marker Dropped Nearly 50% in 10 Weeks

Singapore, 38 years old, navigate one of the most aggressive cancers a person can face. He was diagnosed in April 2025 with Stage IV Bile Duct Cancer, an advanced hilar cholangiocarcinoma, a rare and serious cancer of the bile ducts at the liver's gateway. By the time it was found, it had already spread. Surgeons attempted an operation, but the disease had gone too far. A stent was placed to keep bile flowing. And his tumour marker, CA 19.9, the standard blood indicator used to track this type of cancer, had climbed past 15,000 U/mL. For context, the normal upper limit is 37 U/mL.

He quickly start chemotherapy in August 2025. Gemcitabine and Cisplatin, administered in cycles, powerful drugs carrying powerful side effects. The nausea came. So did the vomiting, the bone-deep fatigue, dangerous electrolyte drops that landed him in hospital. His weight fell sharply.

Before ECCT began, his CA 19.9 was recorded at 7,808 U/mL, already significantly reduced from its April peak post chemotherapy. In early September, it spiked briefly above 10,000 U/mL, a temporary climb that flagged to his oncology as a known resistance response. It is worrying, he began a complementary treatment called ECCT to support his fight and body. ECCT is an electric field therapy delivered through a blanket device. It does not replace chemotherapy. It works alongside it, applying low-frequency electric fields thought to interfere with how abnormal cells divide and survive. What happened to his tumour marker over the weeks that followed has greatly motivate him and his family.

The numbers began to move in one direction without resistance.

That is a drop of more than 58% from the September spike, and roughly 46% below where the marker stood before ECCT was introduced. His own oncology team acknowledged that while imaging interpretation was complicated by comparison challenges across different hospitals, the tumour marker was on a clear and consistent downward trend. The ECCT team's own clinical notes echoed the same observation.

He is not cured. I want to be careful and honest about that. But a tumour marker that was hurtling upward in April, that had broken through 10,000 in September, sitting below 4,200 by mid-November, that is definitely something. That is a body responding to the treatment.

For anyone searching for real solution out there for cholangiocarcinoma, or for families sitting in that terrifying space between diagnosis and hope, I offer this story not as a promise, but as evidence that responses do happen.

Names and identifying details have been covered to protect patient privacy. All medical data is drawn directly from verified clinical records and verifiable. This testimonial is for educational purposes only and does not constitute medical advice. Individual outcomes may vary.